BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 25676709)

  • 1. Interleukin-12 enhances the function and anti-tumor activity in murine and human CD8(+) T cells.
    Rubinstein MP; Su EW; Suriano S; Cloud CA; Andrijauskaite K; Kesarwani P; Schwartz KM; Williams KM; Johnson CB; Li M; Scurti GM; Salem ML; Paulos CM; Garrett-Mayer E; Mehrotra S; Cole DJ
    Cancer Immunol Immunother; 2015 May; 64(5):539-49. PubMed ID: 25676709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ex vivo interleukin-12-priming during CD8(+) T cell activation dramatically improves adoptive T cell transfer antitumor efficacy in a lymphodepleted host.
    Rubinstein MP; Cloud CA; Garrett TE; Moore CJ; Schwartz KM; Johnson CB; Craig DH; Salem ML; Paulos CM; Cole DJ
    J Am Coll Surg; 2012 Apr; 214(4):700-7; discussion 707-8. PubMed ID: 22360982
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization and comparison of 'standard' and 'young' tumour-infiltrating lymphocytes for adoptive cell therapy at a Danish translational research institution.
    Donia M; Junker N; Ellebaek E; Andersen MH; Straten PT; Svane IM
    Scand J Immunol; 2012 Feb; 75(2):157-67. PubMed ID: 21955245
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD8 T cell priming in the presence of IFN-α renders CTLs with improved responsiveness to homeostatic cytokines and recall antigens: important traits for adoptive T cell therapy.
    Hervas-Stubbs S; Mancheño U; Riezu-Boj JI; Larraga A; Ochoa MC; Alignani D; Alfaro C; Morales-Kastresana A; Gonzalez I; Larrea E; Pircher H; Le Bon A; Lopez-Picazo JM; Martín-Algarra S; Prieto J; Melero I
    J Immunol; 2012 Oct; 189(7):3299-310. PubMed ID: 22925929
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo elimination of CD25+ regulatory T cells leads to tumor rejection of B16F10 melanoma, when combined with interleukin-12 gene transfer.
    Nagai H; Horikawa T; Hara I; Fukunaga A; Oniki S; Oka M; Nishigori C; Ichihashi M
    Exp Dermatol; 2004 Oct; 13(10):613-20. PubMed ID: 15447721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adoptive T Cell Therapy with IL-12-Preconditioned Low-Avidity T Cells Prevents Exhaustion and Results in Enhanced T Cell Activation, Enhanced Tumor Clearance, and Decreased Risk for Autoimmunity.
    Tucker CG; Mitchell JS; Martinov T; Burbach BJ; Beura LK; Wilson JC; Dwyer AJ; Singh LM; Mescher MF; Fife BT
    J Immunol; 2020 Sep; 205(5):1449-1460. PubMed ID: 32737148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intratumoral interleukin-21 increases antitumor immunity, tumor-infiltrating CD8+ T-cell density and activity, and enlarges draining lymph nodes.
    Søndergaard H; Galsgaard ED; Bartholomaeussen M; Straten PT; Odum N; Skak K
    J Immunother; 2010 Apr; 33(3):236-49. PubMed ID: 20445344
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ex vivo conditioning with IL-12 protects tumor-infiltrating CD8
    Lin L; Rayman P; Pavicic PG; Tannenbaum C; Hamilton T; Montero A; Ko J; Gastman B; Finke J; Ernstoff M; Diaz-Montero CM
    Cancer Immunol Immunother; 2019 Mar; 68(3):395-405. PubMed ID: 30552459
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TGF-beta1 induces preferential rapid expansion and persistence of tumor antigen-specific CD8+ T cells for adoptive immunotherapy.
    Liu S; Etto T; Rodríguez-Cruz T; Li Y; Wu C; Fulbright OJ; Hwu P; Radvanyi L; Lizée G
    J Immunother; 2010 May; 33(4):371-81. PubMed ID: 20386469
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TCRs genetically linked to CD28 and CD3ε do not mispair with endogenous TCR chains and mediate enhanced T cell persistence and anti-melanoma activity.
    Govers C; Sebestyén Z; Roszik J; van Brakel M; Berrevoets C; Szöőr Á; Panoutsopoulou K; Broertjes M; Van T; Vereb G; Szöllősi J; Debets R
    J Immunol; 2014 Nov; 193(10):5315-26. PubMed ID: 25320284
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TLR2 engagement on memory CD8(+) T cells improves their cytokine-mediated proliferation and IFN-gamma secretion in the absence of Ag.
    Cottalorda A; Mercier BC; Mbitikon-Kobo FM; Arpin C; Teoh DY; McMichael A; Marvel J; Bonnefoy-Bérard N
    Eur J Immunol; 2009 Oct; 39(10):2673-81. PubMed ID: 19634192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Persistence, immune specificity, and functional ability of murine mutant ras epitope-specific CD4(+) and CD8(+) T lymphocytes following in vivo adoptive transfer.
    Bristol JA; Schlom J; Abrams SI
    Cell Immunol; 1999 May; 194(1):78-89. PubMed ID: 10357883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IL-17/IFN-γ double producing CD8+ T (Tc17/IFN-γ) cells: a novel cytotoxic T-cell subset converted from Tc17 cells by IL-12.
    Tajima M; Wakita D; Satoh T; Kitamura H; Nishimura T
    Int Immunol; 2011 Dec; 23(12):751-9. PubMed ID: 22039016
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transfer of in vitro-expanded naïve T cells after lymphodepletion enhances antitumor immunity through the induction of polyclonal antitumor effector T cells.
    Tanaka T; Watanabe S; Takahashi M; Sato K; Saida Y; Baba J; Arita M; Sato M; Ohtsubo A; Shoji S; Nozaki K; Ichikawa K; Kondo R; Aoki N; Ohshima Y; Sakagami T; Abe T; Moro H; Koya T; Tanaka J; Kagamu H; Yoshizawa H; Kikuchi T
    PLoS One; 2017; 12(8):e0183976. PubMed ID: 28854279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant effect of IL-12: conversion of peptide antigen administration from tolerizing to immunizing for CD8+ T cells in vivo.
    Schmidt CS; Mescher MF
    J Immunol; 1999 Sep; 163(5):2561-7. PubMed ID: 10452994
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effector CD8+ T-cell Engraftment and Antitumor Immunity in Lymphodepleted Hosts Is IL7Rα Dependent.
    Johnson CB; Riesenberg BP; May BR; Gilreath SC; Li G; Staveley-O'Carroll KF; Garrett-Mayer E; Mehrotra S; Cole DJ; Rubinstein MP
    Cancer Immunol Res; 2015 Dec; 3(12):1364-74. PubMed ID: 26297711
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The stoichiometric production of IL-2 and IFN-γ mRNA defines memory T cells that can self-renew after adoptive transfer in humans.
    Wang A; Chandran S; Shah SA; Chiu Y; Paria BC; Aghamolla T; Alvarez-Downing MM; Lee CC; Singh S; Li T; Dudley ME; Restifo NP; Rosenberg SA; Kammula US
    Sci Transl Med; 2012 Aug; 4(149):149ra120. PubMed ID: 22932225
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T cell receptor (TCR) gene transfer with lentiviral vectors allows efficient redirection of tumor specificity in naive and memory T cells without prior stimulation of endogenous TCR.
    Circosta P; Granziero L; Follenzi A; Vigna E; Stella S; Vallario A; Elia AR; Gammaitoni L; Vitaggio K; Orso F; Geuna M; Sangiolo D; Todorovic M; Giachino C; Cignetti A
    Hum Gene Ther; 2009 Dec; 20(12):1576-88. PubMed ID: 19678763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhancement of adoptive T cell transfer with single low dose pretreatment of doxorubicin or paclitaxel in mice.
    Hsu FT; Chen TC; Chuang HY; Chang YF; Hwang JJ
    Oncotarget; 2015 Dec; 6(42):44134-50. PubMed ID: 26683520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fludarabine modulates immune response and extends in vivo survival of adoptively transferred CD8 T cells in patients with metastatic melanoma.
    Wallen H; Thompson JA; Reilly JZ; Rodmyre RM; Cao J; Yee C
    PLoS One; 2009; 4(3):e4749. PubMed ID: 19270751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.